Amyotrophic Lateral Sclerosis and Gut-modulating Agents: Current Insights and Future Prospects

Thomas Lehman^*
*Correspondence: Thomas Lehman, Department of Pediatric Otolaryngology, Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, 15213, USA, Email:

Keywords

Amyotrophic lateral sclerosis • Gut microbiota • Neurodegeneration

Introduction

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder affecting motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and ultimately death. Despite extensive research, the exact etiology of ALS remains elusive, and therapeutic options are limited. However, emerging evidence suggests a potential link between gut microbiota and ALS pathogenesis, opening up new avenues for therapeutic intervention through gut-modulating agents. This article explores the current understanding of ALS and the role of gut microbiota, as well as the prospects for utilizing gut-modulating agents in ALS treatment.

Literature Review

ALS is characterized by the progressive degeneration of upper and lower motor neurons, leading to muscle weakness, atrophy, and eventually respiratory failure. While the exact cause of ALS remains unknown, various genetic, environmental, and lifestyle factors have been implicated in its pathogenesis. Mutations in genes such as SOD1, C9orf72, TARDBP, and FUS account for a subset of familial ALS cases, while sporadic cases are thought to result from a complex interplay of genetic and environmental factors. Neuroinflammation, oxidative stress, mitochondrial dysfunction, and protein misfolding are among the key pathological mechanisms implicated in ALS. However, recent studies have highlighted the potential involvement of the gutbrain axis in ALS pathogenesis [1].

The gut-brain axis refers to bidirectional communication between the gastrointestinal tract and the central nervous system, mediated by neural, hormonal, and immunological pathways. Emerging evidence suggests that alterations in gut microbiota composition and function may influence neuroinflammation, oxidative stress, and neuronal dysfunction in ALS. Several studies have reported dysbiosis, or imbalance in gut microbial communities, in ALS patients compared to healthy individuals. Changes in the abundance of specific bacterial taxa, as well as alterations in microbial metabolites, have been observed in ALS patients, suggesting a potential role of gut microbiota in disease pathogenesis [2].

Discussion

Moreover, experimental studies in animal models of ALS have provided further support for the involvement of the gut-brain axis in disease progression. Manipulation of gut microbiota through antibiotics, probiotics, or fecal microbiota transplantation has been shown to modulate disease severity and extend lifespan in ALS mice, highlighting the therapeutic potential of targeting the gut microbiota in ALS. Given the emerging role of gut microbiota in ALS pathogenesis, targeting the gut-brain axis with modulating agents represents a promising therapeutic strategy for ALS. These agents aim to restore microbial balance, reduce neuroinflammation, and improve neuronal function in ALS patients [3].

Probiotics, which consist of beneficial bacteria that promote gut health, have been investigated as potential therapeutic agents for ALS. Preclinical studies have shown that administration of specific probiotic strains can attenuate neuroinflammation, delay disease onset, and improve motor function in ALS mice. Clinical trials evaluating the safety and efficacy of probiotics in ALS patients are currently underway, with preliminary results showing promising outcomes. Furthermore, dietary interventions such as the ketogenic diet, which is low in carbohydrates and high in fats, have been proposed as a means to modulate gut microbiota and improve metabolic function in ALS. The ketogenic diet has been shown to alter gut microbial composition, reduce neuroinflammation, and extend lifespan in ALS animal models. Clinical trials investigating the effects of the ketogenic diet on disease progression and symptom management in ALS patients are ongoing [4].

In addition to probiotics and dietary interventions, Fecal Microbiota Transplantation (FMT) represents another potential approach to modulating gut microbiota in ALS. FMT involves transferring fecal matter from healthy donors to ALS patients to restore microbial diversity and function. Preclinical studies have demonstrated the efficacy of FMT in ameliorating neuroinflammation and extending lifespan in ALS mice. Clinical trials evaluating the safety and efficacy of FMT in ALS patients are currently underway, with initial results showing promising outcomes. While the potential of gut-modulating agents in ALS treatment is promising, several challenges need to be addressed.

These include identifying optimal dosing regimens, selecting appropriate patient populations, and understanding the long-term safety and efficacy of these interventions. Furthermore, the complex interplay between gut microbiota, host genetics, and environmental factors in ALS pathogenesis necessitates a personalized approach to treatment [5]. Future research directions in this field include elucidating the mechanisms underlying the gutbrain axis in ALS, identifying biomarkers for patient stratification and treatment response, and developing novel gut-modulating agents with enhanced efficacy and specificity. Collaborative efforts between clinicians, scientists, and industry partners will be essential to advance the development and translation of gutbased therapies for ALS [6].

Conclusion

The gut-brain axis represents a promising therapeutic target for ALS, with growing evidence implicating gut microbiota in disease pathogenesis. Gut-modulating agents such as probiotics, dietary interventions, and fecal microbiota transplantation offer novel approaches to modulating gut microbiota and improving disease outcomes in ALS patients. While challenges remain, ongoing research efforts hold the potential to revolutionize ALS treatment and improve the lives of affected individuals.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Chiò, Adriano, G. Logroscino, B. J. Traynor and J. Collins, et al. "Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature." Neuroepidemiology 41 (2013): 118-130.

   Google Scholar, Crossref, Indexed at

2. Ryman, Sephira, Andrei A. Vakhtin, Sarah Pirio Richardson and Henry C. Lin. "Microbiome–gut–brain dysfunction in prodromal and symptomatic Lewy body diseases." J Neurol 270 (2023): 746-758.

   Google Scholar, Crossref, Indexed at

3. Parra-Cantu, Carolina, Arnulfo Zaldivar-Ruenes, Manuel Martinez-Vazquez and Hector R. Martinez. "Prevalence of gastrointestinal symptoms, severity of dysphagia, and their correlation with severity of amyotrophic lateral sclerosis in a Mexican cohort." Neurodegener Dis 21 (2021): 42-47.

   Google Scholar, Crossref, Indexed at

4. Samara, Verena C., Patricia Jerant, Summer Gibson and Mark Bromberg. "Bowel, bladder, and sudomotor symptoms in ALS patients." J Neurol Sci 427 (2021): 117543.

   Google Scholar, Crossref, Indexed at

5. Wright, Michelle L., Christina Fournier, Madelyn C. Houser and Malú Tansey, et al. "Potential role of the gut microbiome in ALS: a systematic review." Biol Res Nurs 20 (2018): 513-521.

   Google Scholar, Crossref, Indexed at

6. Salvatore, Silvia, Alice Folegatti, Cristina Ferrigno and Licia Pensabene, et al. "To diet or not to diet this is the question in Food-Protein-Induced Allergic Proctocolitis (FPIAP)—A comprehensive review of current recommendations." Nutrients 16 (2024): 589.

   Google Scholar, Crossref, Indexed at